Status:
COMPLETED
Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study
Lead Sponsor:
Amgen
Conditions:
Colon Cancer
Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This is an exploratory phase 1b/2, global, multicenter, single-arm, 2-part (phase 1b and 2) study of conatumumab in combination with panitumumab in patients with Metastatic Colorectal Cancer.
Detailed Description
This is an exploratory phase 1b/2, global, multicenter, single-arm, 2-part (phase 1b and 2) study of conatumumab in combination with panitumumab in patients with Metastatic Colorectal Cancer. The obj...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum
- Radiographically documented disease progression per modified Response Evaluation Criteria in Solid Tumors (RECIST) during or following treatment with fluoropyrimidine, irinotecan, and/or oxaliplatin chemotherapy for Metastatic Colorectal Cancer. Progressive disease must be documented during or ≤ 6 months after the last dose of the most recent chemotherapy regimen prior to enrollment.
- At least 1 uni-dimensionally measurable lesion measuring ≥ 20 mm in one dimension per modified RECIST. Lesion must not be chosen from a previously irradiated field, unless there has been documented disease progression in that field after irradiation and prior to enrollment. All sites of disease must be evaluated.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Available archived paraffin-embedded tumor tissue from the primary tumor or metastasis for submission to the central laboratory
- Man or woman ≥ 18 years of age at the time of enrollment
- Hematologic function within the following limits:
- Absolute neutrophil count (ANC) \> 1.0 x 10\^9 cells/L
- Platelets ≥ 100 x 10\^9/L
- Renal function within the following limits:
- Creatinine \< 2.0 mg/dL
- Hepatic function within the following limits:
- Aspartate aminotransferase (AST) ≤ 2.5 x upper limit of normal (ULN) (≤ 5 x ULN if liver metastases)
- Alanine aminotransferase (ALT) ≤ 2.5 x ULN (≤ 5 x ULN if liver metastases)
- Bilirubin ≤ 2 x ULN
- Metabolic function within the following limits:
- Amylase ≤ 2 x ULN
- Lipase ≤ 2 x ULN
- Magnesium ≥ lower limit of normal
- Negative pregnancy test ≤ 72 hours before enrollment (for woman of childbearing potential only)
- Must have received 1, 2, or 3 prior chemotherapy regimens for Metastatic Colorectal Cancer
- Competent to comprehend, sign, and date the independent ethics committee/institutional review board (IEC/IRB) approved written informed consent
Exclusion
- History of other primary cancer, unless:
- Curatively resected non-melanomatous skin cancer
- Curatively treated cervical carcinoma in situ
- Other primary solid tumor curatively treated with no known active disease present and no treatment administered for ≥ 5 years before enrollment
- Prior treatment with anti-epidermal growth factor receptor (EGFr) inhibitors (eg, cetuximab, erlotinib, gefitinib), unless treatment was received in the adjuvant setting ≥ 6 months before enrollment
- Use of systemic chemotherapy and radiotherapy ≤ 30 days before enrollment
- Use of prior anti-tumor therapies with a short serum half-life (less than 1 week) including prior experimental agents or approved anti-tumor small molecules ≤ 30 days before enrollment
- Use of anti-tumor therapies with a longer serum half-life (eg, bevacizumab) including prior experimental or approved protein/antibodies ≤ 42 days before enrollment
- Any investigational agent or therapy ≤ 30 days before enrollment
- Known allergy or hypersensitivity to any component of panitumumab and/or AMG 655
- History of or known presence of central nervous system (CNS) metastases
- History of interstitial lung disease (eg, pneumonitis, pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest computerized tomography (CT) scan
- Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrollment
- Active inflammatory bowel disease or other active bowel disease causing chronic diarrhea (defined as ≥ Common Terminology Criteria for Adverse Events \[CTCAE\] grade 2 \[CTCAE version 3.0\])
- Known positive test for human immunodeficiency virus (HIV) infection, hepatitis C virus, acute or chronic hepatitis B infection
- Any co-morbid disease or condition that could increase the risk of toxicity (eg, significant ascites, significant pleural effusion)
- Any uncontrolled concurrent illness (eg, infection, bleeding) or history of any medical condition that may interfere with the interpretation of the study results
- Major surgical procedure (requiring general anesthesia) ≤ 28 days or minor surgical procedure (excluding central venous catheter placement) ≤ 14 days before enrollment. Patients must have recovered from surgery related toxicities.
- Other investigational procedures are excluded
- Patient is currently pregnant or breast feeding
- Man or woman of childbearing potential who is not willing to use adequate contraceptive precautions during treatment and for 6 months (for women) or 1 month (for men) after the last investigational product administration. Adequate contraceptive precautions includes double barrier contraceptive methods (eg, diaphragm and condom) or abstinence.
- Previously enrolled into this study
- Patient unwilling or unable to comply with study requirements
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT00630786
Start Date
January 1 2008
End Date
November 1 2010
Last Update
February 6 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.